share_log

Goldman Sachs Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $19

Benzinga ·  Jun 29, 2023 05:41

Goldman Sachs analyst Paul Choi maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $21 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment